Medical diagnostic technology company Salignostics has achieved a significant milestone in HIV testing through a clinical trial conducted in Ethiopia, showcasing the potential of saliva-based diagnostic methods to transform healthcare accessibility. The clinical trial, performed in November 2024, evaluated 100 saliva samples from individuals diagnosed with HIV and healthy participants. Results revealed exceptional diagnostic performance, with sensitivity exceeding 90% and specificity surpassing 98%. These findings validate saliva as a reliable diagnostic medium and highlight the potential for non-invasive testing approaches.
The innovative test eliminates traditional barriers associated with HIV diagnostics, such as the requirement for blood draws and specialized equipment. By offering a cost-effective and user-friendly alternative, Salignostics aims to enhance testing capabilities in regions with limited healthcare infrastructure. The global HIV diagnostics market underscores the significance of this development. Market projections indicate an expansion from $3.88 billion in 2021 to over $7 billion by 2034, with a compound annual growth rate of 7.5%. This growth reflects increasing demand for decentralized and accessible diagnostic solutions.
Dr. Guy Krief, Co-founder and Deputy CEO of Salignostics, emphasized the trial's importance, stating that the technology aims to complement existing HIV testing methods while providing a reliable solution for diverse global communities. Salignostics has previously demonstrated expertise in saliva-based diagnostics through its Salistick pregnancy test, which has sold over 500,000 units across markets including the UK and Israel. The company holds CE, UKCA, and TGA certifications and is expanding its diagnostic portfolio to include potential applications in oral cancer, respiratory conditions, and sexually transmitted infections.
The successful Ethiopian trial represents a significant advancement in addressing critical public health challenges, potentially transforming HIV testing accessibility and empowering individuals with convenient, private diagnostic options. The development aligns with broader market trends toward more accessible healthcare technologies that can be deployed outside traditional clinical settings. As the company continues to validate its technology, the implications extend beyond HIV to other conditions where non-invasive testing could improve early detection and treatment outcomes.
